Potency of antihypertensive therapy with Azilsartan on Walking Activity among Peripheral Artery Disease Patients With hypertention and Intermittent Claudication

Potency of antihypertensive therapy with Azilsartan on Walking Activity among Peripheral Artery Disease Patients With hypertention and Intermittent Claudication - Potency of antihypertensive therapy with Azilsartan on Walking Activity among Peripheral Artery Disease Patients With hypertention and Intermittent Claudication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013670

Enrollment

Registered

2014-04-08

Start date

2014-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral artery disease

Interventions

medication with Azilsartan medication with amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients over 30years old 2 Mean systolic blood pressure of Twice measurement in examination is 140mmHgover or mean diastolic blood pressure is 90mmHgover 3 Patient with claudication and eGFR over 30ml/min/m2 4 Patients with agreement for this study

Exclusion criteria

Exclusion criteria: 1 Patient with Critical limb ischemia 2 Life expectancy 6months 3 Medication with Cablocker or At1receptor blocker 4 inappropriate patient determined from study director

Design outcomes

Primary

Measure	Time frame
recovery ability index(RAI) in walking exercise near infrared spectroscopy	—

Secondary

Measure	Time frame
1 absolute claudication distance, exercise time and Deoxygenated hemoglobin recovery time in walking exercise near infrared spectroscopy. WIQ score. 2 Anckle Brachial pressure Index,Pulse Wave Verocity,flow mediated vasodilatation,LF/HF in holter ECG, meanHR in holter ECG. 3 Blood pressure in Examination room. Mean blood pressure and Blood Pressure Type in 24hr. Ambulatory Blood Pressure Measurement. 4 Myocardial infarction, stroke and acute heart failure required hospitalization. 5 Adverse event of drug	—

Measure

Time frame

1 absolute claudication distance, exercise time and Deoxygenated hemoglobin recovery time in walking exercise near infrared spectroscopy. WIQ score. 2 Anckle Brachial pressure Index,Pulse Wave Verocity,flow mediated vasodilatation,LF/HF in holter ECG, meanHR in holter ECG. 3 Blood pressure in Examination room. Mean blood pressure and Blood Pressure Type in 24hr. Ambulatory Blood Pressure Measurement. 4 Myocardial infarction, stroke and acute heart failure required hospitalization. 5 Adverse event of drug

—

Countries

Japan

Contacts

Public ContactClinical Trials Support Office

Sakakibara Heart Institute Clinical Trials Support Office

tikenjim@shi.heart.or.jp042-314-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026